Exonate rebrands as Foventa Therapeutics to focus on diabetic retinopathy
AI Summary- Exonate Limited changed its name to Foventa Therapeutics and shifted toward NPDR treatment development.
- FOV407 was selected from more than 1,000 designed and synthesised molecules.
- Foventa is preparing a Phase IIb NPDR study after a Type C FDA meeting.